Gabaergic Signaling Pathway In Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
The GABAergic signaling pathway is the major inhibitory neurotransmitter system in the central nervous system (CNS). Gamma-aminobutyric acid (GABA) is the principal inhibitory neurotransmitter, acting through ionotropic GABAA and GABAC receptors (ligand-gated chloride channels) and metabotropic GABAB receptors (G protein-coupled receptors). Dysfunction of GABAergic signaling contributes to network hyperexcitability, seizures, and cognitive deficits in neurodegenerative diseases including Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), and Huntington's disease (HD).
GABA is synthesized from glutamate via two main pathways:
Glutamic acid decarboxylase (GAD)-mediated synthesis: The primary pathway involves GAD, which decarboxylates glutamate to produce GABA. Two isoforms exist:
GABA shunt: A metabolic pathway connecting the citric acid cycle to GABA synthesis:
Key enzymes:
GABAA receptors are ionotropic chloride channels belonging to the Cys-loop receptor family. They are pentameric assemblies composed of subunits (α1-6, β1-3, γ1-3, δ, ε, θ, π).
Structure:
Subunit distribution in brain:
Benzodiazepine binding site: Located at the α-γ interface; positive allosteric modulators enhance GABA binding.
GABAB receptors are metabotropic GPCRs (class C) that mediate slow, inhibitory neurotransmission.
Structure:
Signaling pathways:
GABAC receptors (now termed GABAA-ρ) are ionotropic receptors with distinct pharmacological profiles. They are primarily located in the retina and spinal cord.
GABAergic neuron loss: Reduced numbers of GABAergic interneurons in hippocampus and cortex in AD brains.
GABAA receptor alterations:
Excitotoxicity cascade: GABAergic dysfunction contributes to excitatory-inhibitory imbalance, promoting glutamate-mediated excitotoxicity.
Aβ interactions:
Therapeutic implications:
Basal ganglia circuitry: GABAergic projections from striatum to globus pallidus (GPe, GPi) and substantia nigra pars reticulata (SNr) are critical for motor control.
Dopamine-GABA interactions:
Levodopa-induced dyskinesias:
Therapeutic targets:
Cortical hyperexcitability: Reduced cortical inhibition due to GABAergic dysfunction.
Motor neuron changes:
C9orf72 expansion effects:
Therapeutic approaches:
Striatal medium spiny neuron (MSN) loss: GABAergic MSNs are preferentially affected in HD.
GABAA receptor changes:
Circuit dysfunction:
Therapeutic strategies:
| Protein | Gene | Function |
|---|---|---|
| GAD67 | GAD1 | GABA synthesis |
| GAD65 | GAD2 | Activity-dependent GABA synthesis |
| GABAAα1 | GABRA1 | Major inhibitory receptor subunit |
| GABAAα5 | GABRA5 | Memory and cognition |
| GABAB1 | GABBR1 | Metabotropic receptor |
| GABAB2 | GABBR2 | Signaling subunit |
| Gephyrin | GPHN | Receptor clustering |
| KCC2 | SLC12A5 | Cl- extrusion |
| NKCC1 | SLC12A2 | Cl- import |
GABAA receptor modulators:
GABAB receptor agonists:
GABA uptake inhibitors:
GABAB positive allosteric modulators:
Gene therapy approaches:
The study of Gabaergic Signaling Pathway In Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Palop JJ, Mucke L. Network abnormalities and interneuron dysfunction in Alzheimer disease. Nat Rev Neurosci. 2016;17(12):777-792.
Luna-Munguia H, et al. GABAergic signaling in neurodegenerative diseases. Brain Res Bull. 2021;176:87-95.
Bhattacharya A, et al. GABA receptors as therapeutic targets in Parkinson's disease. Neuropharmacology. 2021;191:108556.
Ross CA, et al. Huntington disease: GABAergic system in pathogenesis and treatment. J Huntingtons Dis. 2021;10(3):293-306.
Petroff OA. GABA and glutamate in the human brain. Neuroscientist. 2002;8(6):562-573.
Rudolph U, Mohler H. GABA-based therapeutic approaches: GABAA receptor subtype-selective modulators. Curr Opin Pharmacol. 2014;14:18-23.
Typlt M, et al. GABAergic dysfunction in ALS: implications for motor neuron excitability. Brain. 2022;145(1):1-15.
Möhler H. GABAA receptors in central nervous system disease: anxiety, epilepsy, and insomnia. J Recept Signal Transduct Res. 2006;26(6):731-740.
Nava-Mesa MO, et al. GABAergic signaling in Alzheimer's disease: new therapeutic targets. J Alzheimers Dis. 2014;40(2):251-266.
Cryan JF, Kaupmann K. Don't worry 'B' happy: a role for GABAB receptors in anxiety and depression. Trends Pharmacol Sci. 2005;26(1):36-43.
🔴 Low Confidence
| Dimension | Score |
|---|---|
| Supporting Studies | 10 references |
| Replication | 0% |
| Effect Sizes | 25% |
| Contradicting Evidence | 33% |
| Mechanistic Completeness | 50% |
Overall Confidence: 36%